Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

This news summary includes discussions on the legality of Obamacare's preventive care, health impacts of pollution in India, ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.